Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Future Oncol ; 20(22): 1565-1573, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38861296

RESUMEN

Aim: There is little consensus on salvage management of glioblastoma after recurrence, for lack of evidence.Materials & methods: A retrospective study of treatments in patients with recurrent glioblastoma.Results: Surgery at recurrence was related to better overall survival (OS) and progression-free survival (PFS). Surgery at recurrence, Karnofsky index, MGMT methylation status, younger age at diagnosis and number of chemotherapy cycles were positive factors for OS and PFS. The benefit of OS was relevant for a second surgery performed at least 9 months after the first one. Systemic treatments after the second surgery were linked to an improved PFS.Conclusion: Younger age, Karnofsky index, MGMT methylation status and a median time between surgeries ≥9 months may be criteria for eligibility for surgery at recurrence.


[Box: see text].


Asunto(s)
Neoplasias Encefálicas , Glioblastoma , Recurrencia Local de Neoplasia , Selección de Paciente , Humanos , Glioblastoma/cirugía , Glioblastoma/mortalidad , Glioblastoma/patología , Glioblastoma/genética , Femenino , Masculino , Persona de Mediana Edad , Neoplasias Encefálicas/cirugía , Neoplasias Encefálicas/mortalidad , Neoplasias Encefálicas/patología , Estudios Retrospectivos , Anciano , Adulto , Terapia Recuperativa , Reoperación/estadística & datos numéricos , Supervivencia sin Progresión , Metilasas de Modificación del ADN/genética , Proteínas Supresoras de Tumor , Enzimas Reparadoras del ADN
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA